-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Descartes-11 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Descartes-11 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Descartes-11 in Relapsed Multiple Myeloma Drug Details: Descartes-11 is developing for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Descartes-11 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Descartes-11 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Descartes-11 in Refractory Multiple Myeloma Drug Details: Descartes-11 is developing for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6035 in Relapsing Multiple Sclerosis (RMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6035 in Relapsing Multiple Sclerosis (RMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6035 in Relapsing Multiple Sclerosis (RMS) Drug Details: RG-6035 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Adenoid Cystic Carcinoma (ACC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Apatinib Mesylate in Adenoid Cystic Carcinoma (ACC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Adenoid Cystic Carcinoma (ACC) Drug...
-
Product Insights
Myasthenia Gravis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myasthenia Gravis - Drugs In Development, 2023’, provides an overview of the Myasthenia Gravis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Respiratory Distress Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Respiratory Distress Syndrome - Drugs In Development, 2023’, provides an overview of the Respiratory Distress Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Acute Respiratory Distress Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Respiratory Distress Syndrome - Drugs In Development, 2023’, provides an overview of the Acute Respiratory Distress Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Ochoa Project
The Ochoa Project is a potash project in United States. It is currently at the feasibility stage. Empower your strategies with our Ochoa Project report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Descartes-11 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Descartes-11 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Descartes-11 in Refractory Multiple Myeloma Drug Details:Descartes-11 is developing for the treatment...